Biotech Startups Trading IPO Filings For Selling Block – BIO Panel
Executive Summary
The goal of a biotech startup appears to have shifted away from a focus on entering the public market through an IPO in favor of building the company to become an acquisition target
You may also be interested in...
Novartis Gains Hepatitis Market Access Through Idenix Majority Stake
Novartis is adding three novel hepatitis products to its antiviral pipeline through a 51% stake in the privately held biotech company Idenix
Novartis Gains Hepatitis Market Access Through Idenix Majority Stake
Novartis is adding three novel hepatitis products to its antiviral pipeline through a 51% stake in the privately held biotech company Idenix
Dendreon/Corvas merger in peril?
Several large Corvas shareholders oppose acquisition by Dendreon, maintaining that deal does not fairly value company. One proposal would liquidate the company ("The Pink Sheet" March 3, p. 25)...